Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $69.5550, but opened at $65.10. Basilea Pharmaceutica shares last traded at $65.10, with a volume of 11 shares trading hands.
Basilea Pharmaceutica Stock Performance
The company has a debt-to-equity ratio of 0.59, a current ratio of 5.11 and a quick ratio of 4.68. The firm’s 50 day simple moving average is $69.99 and its 200-day simple moving average is $67.28.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
